Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 8Unknown 4Not yet recruiting 3Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 3Biliary Tract Neoplasms 3Adenocarcinoma 2Pancreatic Neoplasms 1NSCLC 1Klatskin Tumor 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 7Cisplatin 6durvalumab 5pembrolizumab 4gemcitabine-oxaliplatin regimen 3S 1 (combination) 3Carboplatin 3Trastuzumab 2Paclitaxel 2Capecitabine 2tucatinib 1tremelimumab 1merestinib 1irinotecan sucrosofate 1envafolimab 1Tegafur 1Ramucirumab 1Radiation 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Itraconazole 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Fulvestrant 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Biliary Tract Neoplasms × S 1 (combination) × Clear all
NCT05771480 2026-04-21

TOURMALINE

AstraZeneca

Phase 3 Active not recruiting
142 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06490107 2024-07-08

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡